Recro Pharma (REPH) Reports Q2 Loss of $0.83/Share

Recro Pharma (NASDAQ: REPH) reported Q2 EPS of ($0.83), versus ($0.17) reported last year. Revenue for the quarter came in at $17.3 million, versus $18.7 million reported last year.

For earnings history and earnings-related data on Recro Pharma (REPH) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Xylem names Andrea van der Berg as CFO, effective Sept. 2026
• Benchmark Reiterates Buy Rating on H World Group Ltd. (HTHT) Following Q2 Print